PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
66.07%
Positive EBIT growth while CRON.TO is negative. John Neff might see a substantial edge in operational management.
66.07%
Positive operating income growth while CRON.TO is negative. John Neff might view this as a competitive edge in operations.
71.07%
Positive net income growth while CRON.TO is negative. John Neff might see a big relative performance advantage.
71.05%
Positive EPS growth while CRON.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
71.05%
Positive diluted EPS growth while CRON.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.38%
Share reduction while CRON.TO is at 25.88%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.38%
Reduced diluted shares while CRON.TO is at 25.88%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
46.07%
OCF growth under 50% of CRON.TO's 234.45%. Michael Burry might suspect questionable revenue recognition or rising costs.
46.07%
FCF growth under 50% of CRON.TO's 94.16%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-264.77%
Negative 10Y OCF/share CAGR while CRON.TO stands at 199.63%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-264.77%
Negative 5Y OCF/share CAGR while CRON.TO is at 106.62%. Joel Greenblatt would question the firm’s operational model or cost structure.
-264.77%
Negative 3Y OCF/share CAGR while CRON.TO stands at 115.92%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
78.58%
Positive 10Y CAGR while CRON.TO is negative. John Neff might see a substantial advantage in bottom-line trajectory.
78.58%
5Y net income/share CAGR 1.25-1.5x CRON.TO's 66.60%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
78.58%
Positive short-term CAGR while CRON.TO is negative. John Neff would see a clear advantage in near-term profit trajectory.
-13.10%
Negative equity/share CAGR over 10 years while CRON.TO stands at 1410.50%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-13.10%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-13.10%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.75%
Firm’s AR is declining while CRON.TO shows 23.99%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-5.84%
Negative asset growth while CRON.TO invests at 1.85%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-1.56%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-66.07%
We cut SG&A while CRON.TO invests at 8.16%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.